Moshe C. Ornstein
Expertise in
27
conditions

Dr. Moshe C. Ornstein

Hematology | Oncology
9500 Euclid Avenue, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
21 Years of Experience
Referral may be required
Expertise in
27
conditions
9500 Euclid Avenue, 
Cleveland, OH 

Overview

Moshe Ornstein is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 21 years.

Dr. Ornstein is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Gamma Knife Radiosurgery.

Dr. Ornstein is board certified in American Board Of Internal Medicine, 2017. He is actively involved in clinical research, co-authoring 85 peer reviewed articles and participating in 6 clinical trials. Dr. Ornstein is currently accepting new patients.

Graduate Institution

Touro College, 2005.0

Residency

Cleveland Clinic

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Board Certifications

American Board Of Internal Medicine, 2017

Fellowships

Cleveland Clinic

Hospital Affiliations

Hillcrest Hospital
Cleveland Clinic Avon Hospital
Cleveland Clinic
Medina Hospital
Akron General Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195
Other Locations
Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
The Cleveland Clinic Foundation Oncology
9500 Euclid Ave, Cleveland, OH 44195

Additional Areas of Focus

Dr. Ornstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Avelumab
Study Phase: Phase 2
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With Apalutamide and Leuprolide
The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With Apalutamide and Leuprolide
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 5 Less Clinical Trials

85 Total Publications

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Valent is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Valent is currently accepting new patients.

Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Pohlman is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Pohlman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pohlman is currently accepting new patients.

Expertise in
27
conditions
Dr. Allison M. Winter
Hematology | Oncology
Expertise in
27
conditions
Dr. Allison M. Winter
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Allison Winter is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Winter is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Winter is currently accepting new patients.

Frequently Asked Questions about Dr. Moshe C. Ornstein

How do I make an appointment with Dr. Moshe C. Ornstein?

You can book an appointment with Dr. Moshe C. Ornstein by calling their office at 866-223-8100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Moshe C. Ornstein a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Moshe C. Ornstein is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Moshe C. Ornstein specialize in?

While Dr. Moshe C. Ornstein is a Hematology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Moshe C. Ornstein participate in research or clinical trials?

Yes. Dr. Moshe C. Ornstein has published 85 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Moshe C. Ornstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Moshe C. Ornstein accept my insurance?

Dr. Moshe C. Ornstein accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 866-223-8100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ornstein's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 15 Advanced Conditions
View All 73 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile